Editas Medicine, Inc.

Editas Medicine, Inc.

2.16
CHF
-0.76
(-26.14%)
-0.52EPS
340.88MMarket Cap
Feb 25Next Earn

Total Valuation

CHF

As of September 30, 2026, Editas Medicine, Inc. carries a market capitalization of 340.88M, placing it among publicly traded companies globally. Its enterprise value stands at 193.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap340.88M
Enterprise Value193.83M

Important Dates

Editas Medicine, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, Editas Medicine, Inc. has 152.90M shares outstanding.

Shares Outstanding152.90M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.24, and the price-to-book ratio stands at 4.83.

PS Ratio6.24
PB Ratio4.83
P/TBV Ratio4.83
P/FCF Ratio-2.82
P/OCF Ratio-2.82

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 4.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 193.83M versus a market cap of 340.88M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.66

Financial Position

As of September 30, 2026, Editas Medicine, Inc. maintains a current ratio of 2.82, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.49, indicating elevated leverage, while an interest coverage ratio of -26.72 demonstrates limited ability to service its debt obligations.

Current Ratio2.82
Quick Ratio2.77
Debt / Equity16.49
Debt / EBITDA-0.19
Interest Coverage-26.72

Financial Efficiency

CHF

Over the twelve months ended September 30, 2026, Editas Medicine, Inc. posted a negative return on equity (ROE) of -147.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.30, reflecting losses generated across the asset base. The company generates approximately 477,818.02 in revenue per employee across its workforce of 87.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-147.44
Return on Assets (ROA)-34.30
Revenue Per Employee477,818.02
Employee Count87.00

Stock Price Statistics

As of the close on July 31, 2026, Editas Medicine, Inc.'s stock has gained approximately 89.46% over the past 52 weeks.

52-Week Price Change89.46%

Income Statement

CHF

Over the twelve months ended September 30, 2026, Editas Medicine, Inc. generated 41.57M in revenue and converted that into -60.26M in net income, yielding earnings per share of -0.52. EBITDA reached -61.32M, while operating income came in at -69.41M.

Revenue41.57M
Operating Income-69.41M
Pretax Income-60.26M
Net Income-60.26M
EBITDA-61.32M
EBIT-63.07M
Earnings Per Share (EPS)-0.52

Balance Sheet

CHF

As of September 30, 2026, Editas Medicine, Inc. holds 158.68M in cash and equivalents against 11.63M in total debt, resulting in a net debt position of -77.73M. Total book value stands at 70.51M, with working capital of 108.78M providing operational flexibility.

Cash & Cash Equivalents158.68M
Total Debt11.63M
Net Debt-77.73M
Equity (Book Value)70.51M
Book Value Per Share0.46
Working Capital108.78M

Cash Flow

CHF

Editas Medicine, Inc. produced -91.94M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -215,246.82 in capital expenditures, free cash flow totaled -92.16M - equivalent to -0.79 per share.

Operating Cash Flow-91.94M
Capital Expenditures-215,246.82
Free Cash Flow-92.16M
FCF Per Share-0.79

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -166.97 and net profit margin of -144.95 provide insight into operational efficiency.

Operating Margin-166.97
Pretax Margin-144.95
Profit Margin-144.95
EBITDA Margin-147.52

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -35.50: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -32.89, meaning Editas Medicine, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-32.89
FCF Yield-35.50

Scores

As of September 30, 2026, Editas Medicine, Inc. has an Altman Z-Score of -9.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-9.31